The earnings call presented several positive developments, including strong financial health, upcoming trial data, and completion of enrollment for a key program. However, significant challenges remain, such as regulatory hurdles and the complexity of diagnosing and treating FTD. The balance of promising advancements and existing challenges suggests a cautiously optimistic outlook.

Company Guidance

During the Alector Second Quarter and Midyear 2025 Earnings Conference Call, the company provided guidance on several key metrics. They reported a strong cash position of $307.3 million, which is expected to fund operations into the second half of 2027. For fiscal year 2025, Alector anticipates collaboration revenue to be between $13 million and $18 million, with total research and development expenses projected at $130 million to $140 million. General and administrative expenses are forecasted to range from $55 million to $65 million. The company is focused on advancing its late-stage clinical programs, particularly the Phase III INFRONT-3 trial for latozinemab, with pivotal data expected by mid-fourth quarter. They are also progressing the Phase II trial of AL101 for early Alzheimer's disease, with trial completion expected in 2026. Alector highlighted their proprietary technology platform, which supports their preclinical pipeline, including a brain-penetrant anti-amyloid beta antibody for Alzheimer's and an engineered GCase enzyme replacement therapy for Parkinson's disease.

Upcoming INFRONT-3 Trial Data

Alector is anticipating top-line data from their Phase III INFRONT-3 trial of latozinemab by mid-Q4 2025. This trial is pivotal as it targets frontotemporal dementia due to the GRN gene mutation, a rare form of dementia with no approved therapy.

Strong Financial Position

The company closed the quarter with $307.3 million in cash, expected to provide runway into the second half of 2027. This financial strength supports their strategic objectives.

Completion of AL101 Phase II Enrollment

The enrollment for the Phase II trial of AL101 in early Alzheimer's disease was completed in April, with trial completion expected in 2026. AL101 aims to elevate progranulin levels, similar to latozinemab, for more prevalent neurodegenerative diseases.

Progranulin Elevation as a Key Endpoint

The FDA has recommended including plasma progranulin as a co-primary endpoint in the INFRONT-3 trial, highlighting its importance as a biologically meaningful marker in FTD-GRN.

Alector (ALEC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALEC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.39 / -	-0.43	―	―	―
Aug 07, 2025	2025 (Q2)	-0.46 / -0.30	-0.4	25.00% (+0.10)	―
May 08, 2025	2025 (Q1)	-0.48 / -0.41	-0.38	-7.89% (-0.03)	―	―
Feb 26, 2025	2024 (Q4)	-0.62 / -0.02	-0.49	95.92% (+0.47)	―
Nov 06, 2024	2024 (Q3)	-0.53 / -0.43	-0.53	18.87% (+0.10)	―	―
Aug 07, 2024	2024 (Q2)	-0.50 / -0.40	0.02	-2100.00% (-0.42)	―
May 08, 2024	2024 (Q1)	-0.51 / -0.38	-0.55	30.91% (+0.17)	―	―
Feb 27, 2024	2023 (Q4)	-0.77 / -0.49	-0.63	22.22% (+0.14)
Nov 07, 2023	2023 (Q3)	-0.66 / -0.53	-0.56	5.36% (+0.03)	―	―
Aug 03, 2023	2023 (Q2)	-0.81 / 0.02	0.12	-83.33% (-0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALEC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$1.46	$2.15	+47.26%
May 08, 2025	$1.04	$1.17	+12.50%
Feb 26, 2025	$1.72	$1.66	-3.49%
Nov 06, 2024	$5.24	$5.64	+7.63%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alector Inc (ALEC) report earnings?

Alector Inc (ALEC) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Alector Inc (ALEC) earnings time?

Alector Inc (ALEC) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALEC EPS forecast?

ALEC EPS forecast for the fiscal quarter 2025 (Q3) is -0.39.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing